BackAbbvie Overview
Abbvie Inc

Abbvie Target Price

Analysts' average 12-month price target for Abbvie is $280.

Get informed when a big investor buys or sells

+ Follow

Share Price

$247.91

Average Target Price

$279.8412.9% upside

19 analysts in the last 4 months

High: $300 | Low: $235

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Guggenheim$28816.2% upsideOpen
2026-08-03Morgan Stanley$29619.4% upsideOpen
2026-08-03Canaccord GenuityGary Nachman$29017% upsideOpen
2026-07-29Barclays$30021% upsideOpen
2026-07-22Canaccord Genuity$28213.8% upsideOpen
2026-07-13UBS$2604.9% upsideOpen
2026-07-13BMO Capital$30021% upsideOpen
2026-07-10RBC CapitalTrung Huynh$28012.9% upsideOpen
2026-07-10Wells Fargo$29519% upsideOpen
2026-07-09Guggenheim$2615.3% upsideOpen
2026-07-06HSBC$30021% upsideOpen
2026-07-06Cantor Fitzgerald$2656.9% upsideOpen
2026-06-23Canaccord Genuity$27310.1% upsideOpen
2026-06-22Wells Fargo$2604.9% upsideOpen
2026-05-15Evercore ISI$2355.2% downsideOpen
2026-05-14Piper Sandler$29820.2% upsideOpen
2026-04-30Morgan Stanley$27812.1% upsideOpen
2026-04-23Piper Sandler$29418.6% upsideOpen
2026-04-20Canaccord Genuity$2625.7% upsideOpen
2026-04-10GuggenheimVamil Divan$2490.4% upsideOpen
2026-04-08Cantor Fitzgerald$2403.2% downsideOpen
2026-02-24RBC CapitalTrung Huynh$2604.9% upsideOpen
2026-02-19Barclays$27510.9% upsideOpen
2026-02-18Piper Sandler$29920.6% upsideOpen
2026-02-05UBS$2307.2% downsideOpen
2026-02-04Evercore ISIGavin Clark-Gartner$2288% downsideOpen
2026-01-28Goldman SachsAsad Haider$22310% downsideOpen
2026-01-20Berenberg Bank$27510.9% upsideOpen
2026-01-15BMO CapitalEvan David Seigerman$2584.1% upsideOpen
2026-01-07UBS$2403.2% downsideOpen
2025-12-12Morgan Stanley$2698.5% upsideOpen
2025-12-10HSBC$2656.9% upsideOpen
2025-11-05Piper SandlerDavid Amsellem$28916.6% upsideOpen
2025-11-03Raymond JamesGary Nachman$2563.3% upsideOpen
2025-10-20Guggenheim$2422.4% downsideOpen
2025-10-17Raymond JamesGary Nachman$2500.8% upsideOpen
2025-10-10Piper Sandler$28414.6% upsideOpen
2025-10-09Cantor Fitzgerald$2500.8% upsideOpen
2025-10-03UBS$2511.2% upsideOpen
2025-10-02HSBC$2259.2% downsideOpen
2025-09-15Cantor FitzgeraldCarter Gould$2451.2% downsideOpen
2025-02-03Raymond JamesGary Nachman$22011.3% downsideOpen
2025-02-03BMO CapitalEvan Seigerman$21513.3% downsideOpen
2024-11-12BMO CapitalEvan David Seigerman$20816.1% downsideOpen
2024-10-31BMO CapitalEvan David Seigerman$2288% downsideOpen
2024-10-31Bank of America SecuritiesCharlie Yang$21015.3% downsideOpen
2024-10-31CitigroupGeoff Meacham$2268.8% downsideOpen
2024-10-18Bank of America SecuritiesGeoff Meacham$19521.3% downsideOpen
2024-10-17BernsteinCourtney Breen$20318.1% downsideOpen
2024-08-23Raymond JamesChristopher Raymond$20915.7% downsideOpen

Abbvie (ABBV) FAQ

Abbvie posts a target price of $280. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $280 for ABBV means covering analysts, on average, see the stock 12.9% upside of $247.91 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for ABBV's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Abbvie's other metric pages and overview cover the third.

Judging Abbvie against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $280 here, then scan peer and history charts to see if the gap is persistent.